Profile data is unavailable for this security.
About the company
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
- Revenue in USD (TTM)247.00m
- Net income in USD-353.00m
- Incorporated2015
- Employees601.00
- LocationArcus Biosciences Inc3928 Point Eden WayHAYWARD 94545-3719United StatesUSA
- Phone+1 (510) 694-6200
- Fax+1 (302) 730-1370
- Websitehttps://arcusbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.48bn | 624.00 | -- | 11.33 | -- | 8.96 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | 443,871.80 | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -30.92 | -- |
| Disc Medicine Inc | 0.00 | -212.18m | 2.54bn | 155.00 | -- | 3.41 | -- | -- | -5.98 | -5.98 | 0.00 | 19.53 | 0.00 | -- | -- | 0.00 | -32.55 | -30.94 | -34.12 | -32.93 | -- | -- | -- | -- | -- | -- | 0.0379 | -- | -- | -- | -94.03 | -- | -- | -- |
| Wave Life Sciences Ltd | 42.73m | -204.38m | 2.61bn | 317.00 | -- | 5.01 | -- | 61.02 | -1.21 | -1.21 | 0.2534 | 2.80 | 0.0863 | -- | 31.67 | 134,785.50 | -41.26 | -44.67 | -52.09 | -71.58 | -- | -- | -478.33 | -208.12 | -- | -- | 0.00 | -- | -60.55 | 16.31 | -110.68 | -- | -11.71 | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.61bn | 240.00 | -- | 3.33 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Travere Therapeutics Inc | 490.73m | -50.26m | 2.72bn | 497.00 | -- | 23.38 | 259.86 | 5.55 | -0.603 | -0.3293 | 5.30 | 1.26 | 0.8184 | 1.71 | 9.15 | 987,382.30 | -8.38 | -37.69 | -11.99 | -48.59 | 97.89 | 96.60 | -10.24 | -116.71 | 2.70 | -- | 0.7308 | -- | 110.45 | 19.87 | 84.32 | -- | 18.81 | -- |
| Veracyte Inc | 517.15m | 66.35m | 2.86bn | 755.00 | 44.20 | 2.18 | 32.60 | 5.53 | 0.8147 | 0.8147 | 6.45 | 16.50 | 0.3822 | 7.31 | 11.34 | 684,960.30 | 4.90 | -1.69 | 5.17 | -1.78 | 70.10 | 67.87 | 12.83 | -5.22 | 7.81 | -- | 0.00 | -- | 16.01 | 34.50 | 174.89 | -- | 27.81 | -- |
| Vera Therapeutics Inc | 0.00 | -299.62m | 2.88bn | 249.00 | -- | 4.77 | -- | -- | -4.66 | -4.66 | 0.00 | 8.48 | 0.00 | -- | -- | 0.00 | -43.10 | -46.45 | -45.69 | -50.25 | -- | -- | -- | -- | -- | -- | 0.1102 | -- | -- | -- | -96.92 | -- | 44.79 | -- |
| Ideaya Biosciences Inc | 218.71m | -113.70m | 2.90bn | 145.00 | -- | 2.84 | -- | 13.27 | -1.30 | -1.30 | 2.46 | 11.65 | 0.1959 | -- | 73.20 | 1,508,345.00 | -10.18 | -18.78 | -10.68 | -20.00 | -- | -- | -51.99 | -185.86 | -- | -- | 0.00 | -- | 3,024.43 | 62.11 | 58.58 | -- | 36.87 | -- |
| Beam Therapeutics Inc | 139.74m | -79.99m | 2.92bn | 511.00 | -- | 2.36 | -- | 20.91 | -0.9703 | -0.9703 | 1.41 | 12.17 | 0.1081 | -- | -- | 273,469.70 | -6.19 | -19.28 | -6.94 | -22.57 | -- | -- | -57.24 | -176.36 | -- | -- | 0.00 | -- | 120.01 | 466.27 | 78.77 | -- | -1.79 | -- |
| Arcus Biosciences Inc | 247.00m | -353.00m | 3.00bn | 601.00 | -- | 4.75 | -- | 12.15 | -3.30 | -3.30 | 2.30 | 5.04 | 0.2158 | -- | 12.05 | 410,981.70 | -30.84 | -18.85 | -38.54 | -22.29 | -- | -- | -142.92 | -103.61 | -- | -- | 0.1356 | -- | -4.26 | 26.08 | -24.73 | -- | -8.12 | -- |
| Viridian Therapeutics Inc | 70.85m | -342.60m | 3.09bn | 252.00 | -- | 5.22 | -- | 43.64 | -4.00 | -4.00 | 0.8355 | 7.09 | 0.0863 | -- | -- | 281,146.80 | -41.73 | -44.39 | -44.98 | -47.63 | -- | -- | -483.57 | -1,390.51 | -- | -- | 0.1044 | -- | 23,359.93 | 132.18 | -26.91 | -- | 63.78 | -- |
| Edgewise Therapeutics Inc | 0.00 | -167.80m | 3.19bn | 146.00 | -- | 6.04 | -- | -- | -1.63 | -1.63 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -32.29 | -28.13 | -33.96 | -29.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.40 | -- | 4.75 | -- |
| Denali Therapeutics Inc | 0.00 | -512.54m | 3.33bn | 503.00 | -- | 3.24 | -- | -- | -2.97 | -2.97 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -40.69 | -25.08 | -44.21 | -29.47 | -- | -- | -- | -348.01 | -- | -- | 0.0055 | -- | -- | -- | -21.23 | -- | 25.15 | -- |
| Spyre Therapeutics Inc | 0.00 | -155.20m | 3.34bn | 102.00 | -- | 5.94 | -- | -- | -2.37 | -2.37 | 0.00 | 9.15 | 0.00 | -- | -- | 0.00 | -22.39 | -53.19 | -24.37 | -59.03 | -- | -- | -- | -3,879.14 | -- | -- | 0.00 | -- | -- | -- | 25.39 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.41bn | 2.90k | -- | 3.37 | -- | 3.75 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Xenon Pharmaceuticals Inc | 7.50m | -345.91m | 3.54bn | 358.00 | -- | 5.85 | -- | 471.97 | -4.36 | -4.36 | 0.0946 | 7.27 | 0.0105 | -- | 5.28 | 20,949.72 | -48.34 | -27.62 | -51.10 | -28.67 | -- | -- | -4,612.13 | -2,733.56 | -- | -- | 0.00 | -- | -- | -25.26 | -47.62 | -- | -21.24 | -- |
Data as of Mar 02 2026. Currency figures normalised to Arcus Biosciences Inc's reporting currency: US Dollar USD
39.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 12.17m | 9.83% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.29m | 5.89% |
| Suvretta Capital Management LLCas of 31 Dec 2025 | 5.19m | 4.19% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 5.05m | 4.08% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.58m | 3.70% |
| Woodline Partners LPas of 31 Dec 2025 | 3.77m | 3.05% |
| Marshall Wace LLPas of 31 Dec 2025 | 3.39m | 2.74% |
| Point72 Asset Management LPas of 31 Dec 2025 | 3.28m | 2.65% |
| Fisher Asset Management LLCas of 31 Dec 2025 | 1.95m | 1.58% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.91m | 1.54% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
